Carreño Juan Manuel, Meade Philip, Sogodogo Na Fatimata, Sano Kaori, Tcheou Johnstone, Raskin Ariel, Singh Gagandeep, Fried Miriam, Loganathan Madhumathi, Francis Benjamin, Bielak Dominika, Jagne Ya Jankey, Salah Hadijatou J, Krammer Florian, de Silva Thushan I
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
iScience. 2025 Jun 13;28(7):112893. doi: 10.1016/j.isci.2025.112893. eCollection 2025 Jul 18.
Early life exposures to influenza viruses may imprint a hemagglutinin group-specific signature on immunity that impacts future responses to infection or vaccination. We assessed the administration of a live attenuated influenza virus (LAIV) vaccine in children. Two LAIV formulations (2016-17 and 2017-18) containing distinct H1N1 components were used. Modest boosting of pre-existing serum stalk reactive titers and enhancement of functional antibody-dependent cellular cytotoxicity activity (ADCC) was observed. The magnitude of stalk antibody induction in children naive to influenza A viruses was low; however, LAIV induced stalk antibodies, increasing the number of children seropositive to both group 1 (G1) and group 2 (G2) influenza viruses. The 2018 LAIV formulation, containing an updated H1N1 component, induced higher stalk reactive antibodies with strong ADCC effector functions to the G1 stalk. No significant changes were detected in NA-reactive antibodies in serum or in stalk- or NA-secretory IgA (sIgA) in oral fluid.
生命早期接触流感病毒可能会在免疫力上留下血凝素组特异性印记,从而影响未来对感染或疫苗接种的反应。我们评估了儿童减毒活流感病毒(LAIV)疫苗的接种情况。使用了两种含有不同H1N1成分的LAIV制剂(2016 - 17年和2017 - 18年)。观察到对预先存在的血清茎反应性滴度有适度增强,以及功能性抗体依赖性细胞毒性活性(ADCC)增强。对甲型流感病毒无免疫力的儿童中茎抗体诱导幅度较低;然而,LAIV诱导了茎抗体,增加了对第1组(G1)和第2组(G2)流感病毒血清学阳性的儿童数量。含有更新H1N1成分的2018年LAIV制剂诱导出更高的茎反应性抗体,并对G1茎具有强大的ADCC效应功能。血清中NA反应性抗体或口腔液中的茎或NA分泌型IgA(sIgA)未检测到显著变化。